Robert Keith
Concepts (291)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 51 | 2023 | 2216 | 5.660 |
Why?
| Epoprostenol | 12 | 2021 | 141 | 2.370 |
Why?
| Carcinoma, Squamous Cell | 11 | 2023 | 622 | 2.340 |
Why?
| Precancerous Conditions | 10 | 2020 | 164 | 2.190 |
Why?
| Chemoprevention | 8 | 2023 | 99 | 2.050 |
Why?
| Cancer Survivors | 4 | 2023 | 225 | 2.020 |
Why?
| Iloprost | 10 | 2023 | 46 | 1.800 |
Why?
| Carmustine | 3 | 2020 | 47 | 1.710 |
Why?
| Smoke | 4 | 2020 | 146 | 1.460 |
Why?
| Bronchi | 10 | 2018 | 253 | 1.450 |
Why?
| Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 967 | 1.270 |
Why?
| Intramolecular Oxidoreductases | 7 | 2018 | 61 | 1.150 |
Why?
| Cytochrome P-450 Enzyme System | 7 | 2018 | 113 | 1.120 |
Why?
| Smoking | 15 | 2019 | 1556 | 1.050 |
Why?
| Telerehabilitation | 1 | 2023 | 25 | 0.910 |
Why?
| Carcinoma in Situ | 5 | 2019 | 45 | 0.880 |
Why?
| Leisure Activities | 1 | 2021 | 28 | 0.790 |
Why?
| Lung | 16 | 2023 | 3830 | 0.770 |
Why?
| Antineoplastic Agents | 7 | 2013 | 1990 | 0.710 |
Why?
| Respiratory System | 1 | 2020 | 144 | 0.700 |
Why?
| Disease Models, Animal | 6 | 2022 | 3799 | 0.700 |
Why?
| Carcinogens | 6 | 2022 | 110 | 0.670 |
Why?
| Biomarkers, Tumor | 9 | 2015 | 1076 | 0.670 |
Why?
| Frizzled Receptors | 2 | 2016 | 23 | 0.660 |
Why?
| Tobacco Smoke Pollution | 1 | 2020 | 235 | 0.620 |
Why?
| Neoplasms, Experimental | 2 | 2018 | 162 | 0.620 |
Why?
| Hospitalists | 1 | 2020 | 176 | 0.580 |
Why?
| Urethane | 4 | 2022 | 40 | 0.580 |
Why?
| Bronchial Neoplasms | 3 | 2011 | 16 | 0.570 |
Why?
| Mice | 23 | 2023 | 15888 | 0.560 |
Why?
| Pulmonary Disease, Chronic Obstructive | 6 | 2020 | 1265 | 0.560 |
Why?
| Antihypertensive Agents | 2 | 2017 | 465 | 0.540 |
Why?
| PPAR gamma | 3 | 2022 | 191 | 0.520 |
Why?
| Telemedicine | 1 | 2023 | 691 | 0.500 |
Why?
| Sputum | 7 | 2019 | 293 | 0.500 |
Why?
| Bronchopulmonary Dysplasia | 1 | 2019 | 337 | 0.500 |
Why?
| Quality of Life | 4 | 2023 | 2457 | 0.490 |
Why?
| Animals | 28 | 2023 | 34133 | 0.460 |
Why?
| Trachea | 1 | 2015 | 238 | 0.460 |
Why?
| Adenocarcinoma | 3 | 2017 | 837 | 0.430 |
Why?
| MicroRNAs | 2 | 2016 | 661 | 0.420 |
Why?
| Mice, Transgenic | 8 | 2018 | 2079 | 0.410 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 1519 | 0.410 |
Why?
| Hyperplasia | 2 | 2011 | 169 | 0.410 |
Why?
| Bronchoscopy | 7 | 2019 | 254 | 0.410 |
Why?
| Cell Transformation, Neoplastic | 4 | 2023 | 320 | 0.390 |
Why?
| Biopsy | 10 | 2023 | 1090 | 0.390 |
Why?
| Exercise | 1 | 2021 | 1743 | 0.360 |
Why?
| Vasodilator Agents | 2 | 2011 | 339 | 0.360 |
Why?
| Humans | 51 | 2023 | 122796 | 0.350 |
Why?
| Receptors, Epoprostenol | 1 | 2008 | 6 | 0.340 |
Why?
| Epithelial-Mesenchymal Transition | 2 | 2022 | 182 | 0.340 |
Why?
| Quinazolines | 1 | 2010 | 243 | 0.320 |
Why?
| Gene Expression Regulation | 2 | 2016 | 2491 | 0.320 |
Why?
| Lung Diseases, Obstructive | 1 | 2007 | 54 | 0.300 |
Why?
| Receptors, Prostaglandin E | 1 | 2006 | 7 | 0.290 |
Why?
| Female | 24 | 2022 | 63629 | 0.270 |
Why?
| Biomedical Research | 1 | 2011 | 630 | 0.260 |
Why?
| Desmoglein 3 | 2 | 2022 | 17 | 0.260 |
Why?
| Neovascularization, Pathologic | 4 | 2015 | 292 | 0.260 |
Why?
| Protein Kinase Inhibitors | 1 | 2010 | 833 | 0.240 |
Why?
| Chromosome Aberrations | 4 | 2013 | 136 | 0.240 |
Why?
| Adrenal Cortex Hormones | 1 | 2007 | 515 | 0.230 |
Why?
| Drug Evaluation, Preclinical | 2 | 2017 | 187 | 0.230 |
Why?
| Anticarcinogenic Agents | 2 | 2018 | 70 | 0.220 |
Why?
| Formaldehyde | 1 | 2022 | 50 | 0.220 |
Why?
| Risk Factors | 7 | 2021 | 9381 | 0.220 |
Why?
| Dinoprostone | 4 | 2010 | 193 | 0.220 |
Why?
| Clinical Trials as Topic | 3 | 2013 | 985 | 0.220 |
Why?
| Cross-Sectional Studies | 4 | 2021 | 4734 | 0.220 |
Why?
| Keratin-5 | 1 | 2022 | 47 | 0.210 |
Why?
| Mice, Inbred A | 2 | 2020 | 45 | 0.210 |
Why?
| Tubulin | 1 | 2022 | 126 | 0.200 |
Why?
| Middle Aged | 19 | 2021 | 28563 | 0.200 |
Why?
| Double-Blind Method | 2 | 2019 | 1711 | 0.200 |
Why?
| Placebos | 2 | 2019 | 204 | 0.200 |
Why?
| Confidence Intervals | 2 | 2021 | 339 | 0.200 |
Why?
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 46 | 0.200 |
Why?
| Respiratory Mucosa | 3 | 2015 | 263 | 0.200 |
Why?
| Smokers | 2 | 2019 | 169 | 0.200 |
Why?
| Aged | 17 | 2021 | 20495 | 0.190 |
Why?
| Male | 27 | 2021 | 59639 | 0.190 |
Why?
| Neoplasm Invasiveness | 6 | 2015 | 472 | 0.190 |
Why?
| Air Pollution | 1 | 2023 | 221 | 0.180 |
Why?
| Epithelial Cells | 4 | 2018 | 995 | 0.180 |
Why?
| Carcinogenesis | 1 | 2021 | 184 | 0.180 |
Why?
| United Kingdom | 1 | 2020 | 260 | 0.170 |
Why?
| ErbB Receptors | 3 | 2023 | 571 | 0.170 |
Why?
| Ki-67 Antigen | 4 | 2015 | 114 | 0.170 |
Why?
| Air Pollutants | 1 | 2023 | 331 | 0.170 |
Why?
| Lung Diseases | 3 | 2015 | 764 | 0.170 |
Why?
| Remission Induction | 1 | 2019 | 246 | 0.170 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2010 | 207 | 0.160 |
Why?
| Butylated Hydroxytoluene | 3 | 2006 | 31 | 0.160 |
Why?
| Receptors, Prostaglandin | 1 | 2017 | 26 | 0.160 |
Why?
| Mice, Inbred BALB C | 3 | 2011 | 1245 | 0.150 |
Why?
| Pulmonary Emphysema | 3 | 2007 | 342 | 0.150 |
Why?
| Biological Availability | 1 | 2017 | 129 | 0.150 |
Why?
| Receptors, CXCR4 | 1 | 2017 | 85 | 0.150 |
Why?
| RNA, Messenger | 3 | 2022 | 2720 | 0.150 |
Why?
| Self Report | 1 | 2021 | 730 | 0.150 |
Why?
| Socioeconomic Factors | 1 | 2021 | 1158 | 0.140 |
Why?
| Chromosomal Instability | 2 | 2013 | 18 | 0.140 |
Why?
| Rats | 4 | 2010 | 5426 | 0.140 |
Why?
| Health Status | 1 | 2021 | 758 | 0.130 |
Why?
| Smoking Cessation | 1 | 2019 | 363 | 0.130 |
Why?
| In Situ Hybridization, Fluorescence | 4 | 2010 | 319 | 0.130 |
Why?
| Logistic Models | 1 | 2021 | 1995 | 0.130 |
Why?
| Mitotic Index | 1 | 2015 | 29 | 0.130 |
Why?
| Mental Health | 1 | 2021 | 571 | 0.130 |
Why?
| Signal Transduction | 5 | 2013 | 4902 | 0.130 |
Why?
| Phospholipases A | 2 | 2006 | 102 | 0.130 |
Why?
| Macrophages | 2 | 2020 | 1334 | 0.130 |
Why?
| Macrophages, Alveolar | 3 | 2023 | 364 | 0.130 |
Why?
| Cell Proliferation | 3 | 2018 | 2328 | 0.120 |
Why?
| Neoplasm Grading | 1 | 2015 | 265 | 0.120 |
Why?
| United States | 3 | 2021 | 13272 | 0.120 |
Why?
| Microarray Analysis | 1 | 2013 | 124 | 0.120 |
Why?
| Sensitivity and Specificity | 6 | 2010 | 1855 | 0.120 |
Why?
| Tertiary Prevention | 1 | 2013 | 3 | 0.120 |
Why?
| Treatment Outcome | 4 | 2018 | 9692 | 0.120 |
Why?
| Inflammation | 3 | 2018 | 2598 | 0.120 |
Why?
| Immunoenzyme Techniques | 2 | 2011 | 201 | 0.120 |
Why?
| Stem Cells | 1 | 2018 | 576 | 0.110 |
Why?
| Pulmonary Alveoli | 2 | 2006 | 395 | 0.110 |
Why?
| Cell Line, Tumor | 2 | 2017 | 2904 | 0.110 |
Why?
| Administration, Topical | 1 | 2011 | 154 | 0.100 |
Why?
| Disease Progression | 6 | 2018 | 2546 | 0.100 |
Why?
| Secondary Prevention | 1 | 2013 | 257 | 0.100 |
Why?
| Biomarkers | 4 | 2023 | 3662 | 0.100 |
Why?
| Primary Prevention | 1 | 2013 | 212 | 0.100 |
Why?
| Time Factors | 2 | 2021 | 6682 | 0.100 |
Why?
| Immunohistochemistry | 5 | 2015 | 1727 | 0.090 |
Why?
| Tumor Cells, Cultured | 2 | 2010 | 904 | 0.090 |
Why?
| Cells, Cultured | 2 | 2016 | 4162 | 0.090 |
Why?
| Surveys and Questionnaires | 1 | 2021 | 4882 | 0.090 |
Why?
| Tocopherols | 1 | 2009 | 20 | 0.090 |
Why?
| Isotretinoin | 1 | 2009 | 23 | 0.090 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 1183 | 0.080 |
Why?
| rho GTP-Binding Proteins | 1 | 2009 | 68 | 0.080 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 59 | 0.080 |
Why?
| Cadherins | 1 | 2010 | 190 | 0.080 |
Why?
| Glycoproteins | 1 | 2010 | 323 | 0.080 |
Why?
| Adenoma | 1 | 2010 | 196 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2005 | 783 | 0.080 |
Why?
| 6-Ketoprostaglandin F1 alpha | 2 | 2004 | 21 | 0.080 |
Why?
| Spectral Karyotyping | 1 | 2007 | 5 | 0.080 |
Why?
| Loss of Heterozygosity | 2 | 2013 | 40 | 0.080 |
Why?
| Survival Rate | 1 | 2011 | 1810 | 0.070 |
Why?
| Endothelium, Vascular | 2 | 2007 | 923 | 0.070 |
Why?
| Acrolein | 1 | 2007 | 25 | 0.070 |
Why?
| Cytosol | 2 | 2006 | 229 | 0.070 |
Why?
| Phagocytosis | 1 | 2009 | 368 | 0.070 |
Why?
| Genome-Wide Association Study | 1 | 2013 | 1376 | 0.070 |
Why?
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2006 | 6 | 0.070 |
Why?
| Methylcholanthrene | 1 | 2006 | 18 | 0.070 |
Why?
| Cell Growth Processes | 1 | 2006 | 56 | 0.070 |
Why?
| Amiodarone | 1 | 2006 | 24 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2015 | 4768 | 0.070 |
Why?
| Mice, Knockout | 3 | 2009 | 2737 | 0.070 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 2127 | 0.070 |
Why?
| Periodontal Diseases | 1 | 2006 | 58 | 0.070 |
Why?
| Administration, Inhalation | 1 | 2007 | 664 | 0.070 |
Why?
| Anti-Arrhythmia Agents | 1 | 2006 | 132 | 0.070 |
Why?
| Leukocytes | 1 | 2006 | 295 | 0.060 |
Why?
| Mice, Inbred C57BL | 4 | 2008 | 5020 | 0.060 |
Why?
| Receptor, ErbB-2 | 1 | 2006 | 321 | 0.060 |
Why?
| Pulmonary Embolism | 1 | 2006 | 190 | 0.060 |
Why?
| Case-Control Studies | 5 | 2012 | 3296 | 0.060 |
Why?
| Bronchiolitis | 1 | 2004 | 83 | 0.060 |
Why?
| Genotype | 1 | 2008 | 1943 | 0.060 |
Why?
| Patient Compliance | 1 | 2007 | 561 | 0.060 |
Why?
| Aged, 80 and over | 6 | 2015 | 6845 | 0.050 |
Why?
| Muscles | 1 | 2023 | 336 | 0.050 |
Why?
| Alveolar Epithelial Cells | 1 | 2023 | 98 | 0.050 |
Why?
| Pulmonary Artery | 2 | 2005 | 1097 | 0.050 |
Why?
| Apoptosis | 2 | 2009 | 2532 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 537 | 0.050 |
Why?
| Dyspnea | 1 | 2023 | 214 | 0.050 |
Why?
| Particle Size | 1 | 2023 | 344 | 0.050 |
Why?
| Hemorrhage | 1 | 2006 | 663 | 0.050 |
Why?
| Gene Expression Profiling | 2 | 2005 | 1625 | 0.050 |
Why?
| Particulate Matter | 1 | 2023 | 257 | 0.050 |
Why?
| Neoplasm Proteins | 1 | 2004 | 415 | 0.050 |
Why?
| Weight Gain | 1 | 2004 | 511 | 0.050 |
Why?
| Research Design | 1 | 2007 | 1002 | 0.050 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2000 | 51 | 0.050 |
Why?
| Prevalence | 2 | 2023 | 2442 | 0.050 |
Why?
| Cell Line | 2 | 2018 | 2785 | 0.050 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 59 | 0.050 |
Why?
| Survivors | 1 | 2023 | 440 | 0.050 |
Why?
| Tuberculosis | 1 | 2003 | 266 | 0.050 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 1003 | 0.040 |
Why?
| Sepsis | 1 | 2006 | 546 | 0.040 |
Why?
| Cell Cycle Proteins | 2 | 2018 | 576 | 0.040 |
Why?
| Walking | 1 | 2023 | 435 | 0.040 |
Why?
| Cohort Studies | 2 | 2023 | 5294 | 0.040 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1402 | 0.040 |
Why?
| Environmental Exposure | 1 | 2023 | 427 | 0.040 |
Why?
| gamma Catenin | 1 | 2018 | 17 | 0.040 |
Why?
| Enzyme Inhibitors | 1 | 2022 | 836 | 0.040 |
Why?
| Metaplasia | 1 | 2018 | 59 | 0.040 |
Why?
| Pilot Projects | 1 | 2023 | 1477 | 0.040 |
Why?
| Tobacco Smoking | 1 | 2018 | 22 | 0.040 |
Why?
| Bronchial Diseases | 1 | 2018 | 35 | 0.040 |
Why?
| Cell Division | 1 | 2000 | 788 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2018 | 89 | 0.040 |
Why?
| Time | 1 | 2018 | 81 | 0.040 |
Why?
| Prognosis | 1 | 2006 | 3563 | 0.040 |
Why?
| ROC Curve | 2 | 2010 | 494 | 0.040 |
Why?
| Epithelium | 1 | 2018 | 309 | 0.040 |
Why?
| Adult | 7 | 2018 | 32385 | 0.040 |
Why?
| Hypoxia | 1 | 2003 | 1003 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2005 | 2359 | 0.040 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2000 | 466 | 0.040 |
Why?
| Prospective Studies | 2 | 2023 | 6704 | 0.030 |
Why?
| Phospholipases A2 | 2 | 2006 | 77 | 0.030 |
Why?
| Neoplasm Staging | 2 | 2010 | 1234 | 0.030 |
Why?
| Proto-Oncogene Proteins | 1 | 2018 | 646 | 0.030 |
Why?
| Endoscopy | 1 | 2015 | 267 | 0.030 |
Why?
| Incidence | 2 | 2010 | 2527 | 0.020 |
Why?
| Administration, Oral | 1 | 2012 | 786 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2018 | 2784 | 0.020 |
Why?
| Luciferases | 1 | 2010 | 150 | 0.020 |
Why?
| Mutation | 1 | 2000 | 3493 | 0.020 |
Why?
| Area Under Curve | 1 | 2010 | 303 | 0.020 |
Why?
| International Agencies | 1 | 2009 | 29 | 0.020 |
Why?
| Mice, Inbred ICR | 1 | 2009 | 111 | 0.020 |
Why?
| rhoA GTP-Binding Protein | 1 | 2009 | 80 | 0.020 |
Why?
| rho-Associated Kinases | 1 | 2009 | 85 | 0.020 |
Why?
| Fluorescence | 1 | 2009 | 164 | 0.020 |
Why?
| Cytotoxins | 1 | 2007 | 17 | 0.020 |
Why?
| Platinum | 1 | 2007 | 38 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 432 | 0.020 |
Why?
| Carboplatin | 1 | 2007 | 142 | 0.020 |
Why?
| Bevacizumab | 1 | 2007 | 127 | 0.020 |
Why?
| Blotting, Western | 1 | 2010 | 1225 | 0.020 |
Why?
| Minichromosome Maintenance Complex Component 2 | 1 | 2006 | 4 | 0.020 |
Why?
| Airway Obstruction | 1 | 2009 | 182 | 0.020 |
Why?
| Paclitaxel | 1 | 2007 | 202 | 0.020 |
Why?
| Chemokine CCL8 | 1 | 2006 | 3 | 0.020 |
Why?
| Monocyte Chemoattractant Proteins | 1 | 2006 | 8 | 0.020 |
Why?
| Databases, Nucleic Acid | 1 | 2005 | 35 | 0.020 |
Why?
| Chemokine CCL2 | 1 | 2006 | 126 | 0.020 |
Why?
| Angiogenesis Inhibitors | 1 | 2007 | 223 | 0.020 |
Why?
| Enzymes | 1 | 2005 | 66 | 0.020 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 105 | 0.020 |
Why?
| Tomography, X-Ray Computed | 2 | 2006 | 2500 | 0.020 |
Why?
| Microsomes | 1 | 2004 | 25 | 0.020 |
Why?
| Cell Culture Techniques | 1 | 2007 | 354 | 0.020 |
Why?
| Cyclooxygenase 1 | 1 | 2004 | 22 | 0.020 |
Why?
| Risk | 1 | 2007 | 890 | 0.020 |
Why?
| Species Specificity | 1 | 2005 | 578 | 0.020 |
Why?
| DNA Replication | 1 | 2005 | 214 | 0.020 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 61 | 0.020 |
Why?
| Cluster Analysis | 1 | 2005 | 493 | 0.020 |
Why?
| Prostaglandins | 1 | 2004 | 84 | 0.020 |
Why?
| Tachycardia, Ventricular | 1 | 2006 | 174 | 0.010 |
Why?
| Arachidonic Acid | 1 | 2004 | 121 | 0.010 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2009 | 1181 | 0.010 |
Why?
| Predictive Value of Tests | 1 | 2009 | 1947 | 0.010 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 903 | 0.010 |
Why?
| Cyclooxygenase 2 | 1 | 2004 | 172 | 0.010 |
Why?
| Immunoblotting | 1 | 2004 | 318 | 0.010 |
Why?
| Vital Capacity | 1 | 2004 | 277 | 0.010 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2006 | 633 | 0.010 |
Why?
| Neutrophils | 1 | 2009 | 1246 | 0.010 |
Why?
| Isoenzymes | 1 | 2004 | 303 | 0.010 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 658 | 0.010 |
Why?
| Osteopontin | 1 | 2003 | 39 | 0.010 |
Why?
| Evidence-Based Medicine | 1 | 2007 | 731 | 0.010 |
Why?
| Sialoglycoproteins | 1 | 2003 | 162 | 0.010 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 839 | 0.010 |
Why?
| Forced Expiratory Volume | 1 | 2004 | 562 | 0.010 |
Why?
| Drainage | 1 | 2003 | 165 | 0.010 |
Why?
| Oxidative Stress | 1 | 2009 | 1204 | 0.010 |
Why?
| Sex Factors | 1 | 2007 | 1860 | 0.010 |
Why?
| Antioxidants | 1 | 2006 | 581 | 0.010 |
Why?
| Up-Regulation | 1 | 2005 | 891 | 0.010 |
Why?
| Nuclear Proteins | 1 | 2006 | 618 | 0.010 |
Why?
| Endothelial Cells | 1 | 2007 | 749 | 0.010 |
Why?
| Atrial Fibrillation | 1 | 2006 | 392 | 0.010 |
Why?
| Alleles | 1 | 2004 | 852 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 2007 | 1306 | 0.010 |
Why?
| Lipid Metabolism | 1 | 2004 | 482 | 0.010 |
Why?
| RNA | 1 | 2005 | 854 | 0.010 |
Why?
| Membrane Proteins | 1 | 2004 | 1093 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2003 | 2501 | 0.010 |
Why?
| Risk Assessment | 1 | 2004 | 3213 | 0.010 |
Why?
| Hypertension, Pulmonary | 1 | 2003 | 1900 | 0.010 |
Why?
| Retrospective Studies | 1 | 2005 | 13433 | 0.000 |
Why?
|
|
Keith's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|